[Etanercept in childhood psoriasis].
We present the case of a 10-year old male child with severe incapacitating psoriasis resistant to multiple treatments. He was treated with etanercept successfully in our Dermatology Department. The use of etanercept in children and adolescents with severe psoriasis has been recently approved by the European Medicines Agency. Thus, it has become the first and only biological drug authorized for its use in the child population.
Pérez-Barrio
S
S
Servicio de Dermatología, Hospital de Basurto, Bilbao, Vizcaya, España.
Careaga
J M
JM
D000293:Adolescent; D002648:Child; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D008297:Male; D011565:Psoriasis / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept